Educating effector T cells

CD45RA(bright)/CD11a(bright) CD8+ T cells: effector T cells.

An important aspect of peripheral T cell development is the differentiation from naive into memory cells. To distinguish naive from memory cells, CD45RA and CD11a are commonly used: CD45RA+ or CD11a(dim) T cells are regarded as naive, while CD45RA- or CD11a(bright) T cells are thought to be of memory type. There is, however, a CD8+ T cell subset which is CD45RA+ and at the same time CD11a(brigh...

Antigen-Specific T Cells Maintain an Effector

Heterogeneity of human effector CD4+ T cells

For many years the heterogeneity of CD4+ T-helper (Th) cells has been limited to Th1 and Th2 cells, which have been considered not only to be responsible for different types of protective responses, but also for the pathogenesis of many disorders. Th1 cells are indeed protective against intracellular microbes and they are thought to play a pathogenic role in organ-specific autoimmune and other ...

CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis.

RATIONALE CD4 T cells are involved in the pathogenesis of atherosclerosis, but atherosclerosis-specific CD4 T cells have not been described. Moreover, the chemokine(s) that regulates T-cell trafficking to the atherosclerotic lesions is also unknown. OBJECTIVE In Apoe(-/-) mice with mature atherosclerotic lesions (5 months of high fat diet), we find that most aortic T cells express CCR5 and in...

eradication of established murine skin tumors by cyclic chemoimmunotherapy with cyclophosphamide and effector t cells

background : nonmyeloablative chemotherapy followed by adoptive immunotherapy is an attractive strategy for depleting regulatory t cells in the host. however, its efficacy is transient. here, we aim to investigate whether cyclic chemoim- munotherapy has therapeutic efficacy against cancer. methods :we examined the efficacy of cyclic chemoimmunotherapy with cyclophos- phamide and adoptively tran...